Inhibition of the Soluble Extracellular Domain of E-cadherin: A Novel Tumoricidal drug for Cancers
Monoclonal antibodies that have demonstrated profound antitumor effects both in vitro and in vivo. Background: Over the last decade, the most significant revolutionary advances in oncology have been the introduction and FDA approval of targeted monoclonal antibodies (mAb) against the human epidermal growth factor receptor (HER1-4) family. In combination...
Inventor(s): Sabine Brouxhon, Stephanos Kyrkanides, Marcia Simon, Li Ma, Liqun Wang, Soosan Ghazizadeh
Category(s): Therapeutics, Campus > Stony Brook University